ABVC News and Press, ABVC BioPharma Inc. From 07/18/22

-- Growth to benefit ABVC’s Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematol...

ABVC Biopharma ( NASDAQ: ABVC ) is surging ~18% premarket after the company enrolled a total of 22 subjects in the Phase II Part II clinical study of the its attention-deficit hyperactivity disorder drug, ABV-1505. The company expects to eventually enroll abou...

FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the enrollment progress in the Phase ...

Fremont, CA - ( NewMediaWire ) - July 06, 2022 - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Zacks Small-Cap Research report dated June 7, 2022 values...

ABVC BioPharma ( NASDAQ: ABVC ) on Thursday said that it had got approval from a Thai ethics committee for its phase 2 clinical study protocol for its medical device Vitargus. The study protocol was approved by the Central Research Ethics Committee of the National Rese...

ABVC Biopharma (NASDAQ:ABVC) is trading 12% higher after it expanded its co-development partnership with Rgene Corporation to guide the latter's three drug products through completion of Phase II clinical studies. Under the partnership, BioKey, ABVC’s subsidiary, wi...

FREMONT, CA, June 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that it has expanded its co-developme...

ABVC Biopharma (NASDAQ:ABVC) on Thursday said it had submitted its phase 2 study plan for its vitreous substitute Vitargus to an Australian regulatory ethics committee. ABVC said that if the mid-stage study gets the approval of the Australian Bellberry Human Research Ethics Committee, it...

FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase...

ABVC Biopharma (NASDAQ:ABVC) said on Friday that two of its contracts had been terminated after the parties were unable to agree to the final terms of the loan between BioKey and NeuCen. The first contract, which was announced on May 3, was a $3M clinical services agreement between ...